Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeon BiodesignROCO:6499 +6.71%68 Days Inventory is 24.72 as of Dec. 2025, which is 22% below its 10-year median of 31.72. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.15 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 787 Medical Devices & Instruments companies, Medeon Biodesign ranks better than 97.2% on this metric.
The historical rank and industry rank for Medeon Biodesign's Days Inventory or its related term are showing as below:
ROCO:6499'
s Days Inventory Range Over the Past 10 Years
Min: 17.1 Med: 31.72 Max: 411.6
Current: 29.14
During the past 13 years, Medeon Biodesign's highest Days Inventory was 411.60. The lowest was 17.10. And the median was 31.72.
ROCO:6499's Days Inventory is ranked better than 97.2% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 179.47
vs ROCO:6499: 29.14
Medeon Biodesign's Days Inventory
declined
from Dec. 2024 (45.46) to Dec. 2025 (24.72).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Medeon Biodesign's Inventory Turnover for the
three
months ended in Dec. 2025 was 3.69.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Medeon Biodesign's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 0.22.
Medeon Biodesign (ROCO:6499) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Medeon Biodesign's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Medeon Biodesign's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Medeon Biodesign Days Inventory Related Terms
Medeon Biodesign Days Inventory Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6499 vs ISRG, BDX, MDLN: Days Inventory Comparison
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Days Inventory distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medeon Biodesign (ROCO:6499) has a Days Inventory of 24.72 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Medeon Biodesign and its competitors. This is 22% below median its historical median of 31.72. Over the past decade, Medeon Biodesign's Days Inventory has ranged from 17.10 to 411.60. According to the industry distribution chart, Medeon Biodesign ranks #22 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 2.8%.
Is Medeon Biodesign's Days Inventory too high?
Medeon Biodesign's current Days Inventory of 24.72 is 22% below median its 10-year median of 31.72. Over the past 10 years, this metric has ranged from a low of 17.10 to a high of 411.60. The Medical Devices & Instruments industry median Days Inventory is 179.47. Medeon Biodesign's value of 24.72 is 86.2% below this industry median. Based on the distribution chart, Medeon Biodesign ranks #22 out of 787 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Days Inventory compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #22 out of 787 companies for Days Inventory. This places Medeon Biodesign in the top 3% of its industry — outperforming the majority of peers. The industry median Days Inventory is 179.47. Medeon Biodesign's value of 24.72 is 86.2% below this benchmark. Historically, Medeon Biodesign's own Days Inventory has ranged from 17.10 to 411.60 over the past decade. While the company's 10-year median is 31.72 vs. the industry median of 179.47, Medeon Biodesign has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.47, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current Days Inventory of 24.72 is 86.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Medeon Biodesign and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current Days Inventory is 24.72, which is 22% below median its own 10-year median of 31.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.15, compared to a current price of NT$70.00 — trading 34.7% below its estimated fair value. The current Days Inventory is 24.72, which is 22% below median its 10-year median of 31.72 and 86.2% below the Medical Devices & Instruments industry median of 179.47. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Days Inventory is 24.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$70.00 is trading 34.7% below its estimated GF Value™ of NT$107.15.
GuruFocus considers Medeon Biodesign to be Significantly Undervalued.
Key valuation signals for ROCO:6499:
Days Inventory: 24.72 (22% below median its 10-year median of 31.72)
GF Value™: NT$107.15 vs. price of NT$70.00 (34.7% below fair value)
Industry Position: 86.2% below the Medical Devices & Instruments median (#22 of 787)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score
Get the complete analysis for ROCO:6499
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
